In triple-negative breast cancer cells (4 T1), the overall response rates of PD-1/PDL-1 inhibitors are only 5–30%; in melanoma (B16-F10), tumour recurrence often occurs despite continuous treatment after the initial tumour subsides [2, 3]. This evidence concerns the gene CD274 and neoplasm.